LBA16 Giredestrant (GIRE), an oral selective oestrogen receptor (ER) antagonist and degrader, + everolimus (E) in patients (pts) with ER-positive, HER2-negative advanced breast cancer (ER+, HER2– aBC) previously treated with a CDK4/6 inhibitor (i): Primary results of the phase III evERA BC trial

Authors:
  • EME. Mayer
    E. Mayer
  • STS. Tolaney
    S. Tolaney
  • MMM. Martin
    M. Martin
  • GVG. Vidal
    G. Vidal
  • LML. Moscetti
    L. Moscetti
  • KJK. Jhaveri
    K. Jhaveri
  • ABA. Brufsky
    A. Brufsky
  • WGW. Gradishar
    W. Gradishar
  • ASA. Schneeweiss
    A. Schneeweiss
  • NNN. Niikura
    N. Niikura
  • AFA. Favret
    A. Favret
  • MAM. Alfie
    M. Alfie

Abstract
No abstract available